{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T17:38:01Z","timestamp":1781199481652,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Senju Pharmaceutical Co., Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s10384-023-01022-6","type":"journal-article","created":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T02:01:46Z","timestamp":1692410506000},"page":"668-677","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Additive effects of brimonidine tartrate 0.1%\/brinzolamide 1% fixed-dose combination in prostaglandin analog-treated Japanese glaucoma patients"],"prefix":"10.1007","volume":"67","author":[{"given":"Rei","family":"Sakata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Mizoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misato","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Ohkubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Asato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6810-0583","authenticated-orcid":false,"given":"Makoto","family":"Aihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,19]]},"reference":[{"key":"1022_CR1","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.2165\/11634460-000000000-00000","volume":"72","author":"F Aptel","year":"2012","unstructured":"Aptel F, Chiquet C, Romanet JP. Intraocular pressure-lowering combination therapies with prostaglandin analogues. Drugs. 2012;72:1355\u201371.","journal-title":"Drugs"},{"key":"1022_CR2","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1517\/14656566.8.18.3237","volume":"8","author":"JT Whitson","year":"2007","unstructured":"Whitson JT. Glaucoma: a review of adjunctive therapy and new management strategies. Expert Opin Pharmacother. 2007;8:3237\u201349.","journal-title":"Expert Opin Pharmacother"},{"key":"1022_CR3","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1177\/112067210901900411","volume":"19","author":"WC Stewart","year":"2009","unstructured":"Stewart WC, Kruft B, Nelson LA, Stewart JA. Ophthalmologist attitudes regarding fixed combination treatment for glaucoma in the European union. Eur J Ophthalmol. 2009;19:588\u201393.","journal-title":"Eur J Ophthalmol"},{"key":"1022_CR4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s10384-021-00844-6","volume":"65","author":"M Aihara","year":"2021","unstructured":"Aihara M. Prostanoid receptor agonists for glaucoma treatment. Jpn J Ophthalmol. 2021;65:581\u201390.","journal-title":"Jpn J Ophthalmol"},{"key":"1022_CR5","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s12325-014-0151-7","volume":"31","author":"G Holl\u00f3","year":"2014","unstructured":"Holl\u00f3 G, Vuorinen J, Tuominen J, Huttunen T, Ropo A, Pfeiffer N. Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products. Adv Ther. 2014;31:932\u201344.","journal-title":"Adv Ther"},{"key":"1022_CR6","doi-asserted-by":"publisher","first-page":"e277","DOI":"10.1111\/aos.13568","volume":"96","author":"F Li","year":"2018","unstructured":"Li F, Huang W, Zhang X. Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis. Acta Ophthalmol. 2018;96:e277\u201384.","journal-title":"Acta Ophthalmol"},{"key":"1022_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ophtha.2020.10.022","volume":"128","author":"SJ Gedde","year":"2021","unstructured":"Gedde SJ, Vinod K, Wright MM, Muir KW, Lind JT, Chen PP, et al. Primary open-angle glaucoma preferred practice pattern\u00ae. Ophthalmology. 2021;128:71\u2013150.","journal-title":"Ophthalmology"},{"key":"1022_CR8","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.ophtha.2009.03.050","volume":"116","author":"TE Bournias","year":"2009","unstructured":"Bournias TE, Lai J. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs. Ophthalmology. 2009;116:1719\u201324.","journal-title":"Ophthalmology"},{"key":"1022_CR9","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.ophtha.2009.06.024","volume":"116","author":"JC Tsai","year":"2009","unstructured":"Tsai JC. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology. 2009;116:S30\u20136.","journal-title":"Ophthalmology"},{"key":"1022_CR10","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.2147\/OPTH.S24058","volume":"5","author":"T Mizoguchi","year":"2011","unstructured":"Mizoguchi T, Ozaki M, Wakiyama H, Ogino N. Additive intraocular pressure-lowering effect of dorzolamide 1%\/timolol 0.5% fixed combination on prostaglandin monotherapy in patients with normal tension glaucoma. Clin Ophthalmol (Auckland, NZ). 2011;5:1515\u201320.","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"key":"1022_CR11","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/eye.2016.126","volume":"30","author":"RD Fechtner","year":"2016","unstructured":"Fechtner RD, Myers JS, Hubatsch DA, Budenz DL, DuBiner HB. Ocular hypotensive effect of fixed-combination brinzolamide\/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial. Eye (Lond). 2016;30:1343\u201350.","journal-title":"Eye (Lond)"},{"key":"1022_CR12","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ajo.2016.02.026","volume":"165","author":"RM Feldman","year":"2016","unstructured":"Feldman RM, Katz G, McMenemy M, Hubatsch DA, Realini T. A randomized trial of fixed-dose combination brinzolamide 1%\/brimonidine 0.2% as adjunctive therapy to travoprost 0.004. Am J Ophthalmol. 2016;165:188\u201397.","journal-title":"Am J Ophthalmol"},{"key":"1022_CR13","doi-asserted-by":"publisher","first-page":"e720","DOI":"10.1111\/aos.13401","volume":"95","author":"M Aihara","year":"2017","unstructured":"Aihara M, Adachi M, Matsuo H, Togano T, Fukuchi T, Sasaki N. Additive effects and safety of fixed combination therapy with 1% brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5% timolol in prostaglandin-treated glaucoma patients. Acta Ophthalmol. 2017;95:e720\u20136.","journal-title":"Acta Ophthalmol"},{"key":"1022_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/1120672119878044","volume":"31","author":"F Topouzis","year":"2021","unstructured":"Topouzis F, Goldberg I, Bell K, Tatham AJ, Ridolfi A, Hubatsch D, et al. Brinzolamide\/brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma\/ocular hypertension. Eur J Ophthalmol. 2021;31:103\u201311.","journal-title":"Eur J Ophthalmol"},{"key":"1022_CR15","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.2165\/00002512-200724120-00004","volume":"24","author":"AS Khouri","year":"2007","unstructured":"Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs Aging. 2007;24:1007\u201316.","journal-title":"Drugs Aging"},{"key":"1022_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12325-020-01525-5","volume":"38","author":"AG Konstas","year":"2021","unstructured":"Konstas AG, Schmetterer L, Katsanos A, Hutnik CML, Holl\u00f3 G, Quaranta L, et al. Dorzolamide\/timolol fixed combination: learning from the past and looking toward the future. Adv Ther. 2021;38:24\u201351.","journal-title":"Adv Ther"},{"key":"1022_CR17","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/00055735-200404000-00013","volume":"15","author":"RD Fechtner","year":"2004","unstructured":"Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol. 2004;15:132\u20135.","journal-title":"Curr Opin Ophthalmol"},{"key":"1022_CR18","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1517\/14656566.2014.936850","volume":"15","author":"G Holl\u00f3","year":"2014","unstructured":"Holl\u00f3 G, Topouzis F, Fechtner RD. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Expert Opin Pharmacother. 2014;15:1737\u201347.","journal-title":"Expert Opin Pharmacother"},{"key":"1022_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/00055735-199704000-00010","volume":"8","author":"T Taniguchi","year":"1997","unstructured":"Taniguchi T, Kitazawa Y. The potential systemic effect of topically applied beta-blockers in glaucoma therapy. Curr Opin Ophthalmol. 1997;8:55\u20138.","journal-title":"Curr Opin Ophthalmol"},{"key":"1022_CR20","doi-asserted-by":"publisher","first-page":"4146124","DOI":"10.1155\/2019\/4146124","volume":"2019","author":"L Negri","year":"2019","unstructured":"Negri L, Ferreras A, Iester M. Timolol 0.1% in glaucomatous patients: efficacy, tolerance, and quality of life. J Ophthalmol. 2019;2019:4146124.","journal-title":"J Ophthalmol"},{"key":"1022_CR21","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.2147\/OPTH.S228777","volume":"13","author":"SF Lerner","year":"2019","unstructured":"Lerner SF, Oddone F, Lu DW, Sanseau A, Guarro M, Ridolfi A, et al. Maximum medical therapy: brinzolamide\/brimonidine and travoprost\/timolol fixed-dose combinations in glaucoma and ocular hypertension. Clin Ophthalmol (Auckland, NZ). 2019;13:2411\u20139.","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"key":"1022_CR22","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.ophtha.2018.10.040","volume":"126","author":"RN Weinreb","year":"2019","unstructured":"Weinreb RN, Bacharach J, Fechtner RD, Kahook MY, Wirta D, Burmaster S, et al. 24-hour intraocular pressure control with fixed-dose combination brinzolamide 1%\/brimonidine 0.2%: a multicenter, randomized trial. Ophthalmology. 2019;126:1095\u2013104.","journal-title":"Ophthalmology"},{"key":"1022_CR23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2147\/OPTH.S231402","volume":"14","author":"N Wang","year":"2020","unstructured":"Wang N, Lu DW, Pan Y, Astakhov Y, Iureva T, Adewale A, et al. Comparison of the intraocular pressure-lowering efficacy and safety of the brinzolamide\/brimonidine fixed-dose combination versus concomitant use of brinzolamide and brimonidine for management of open-angle glaucoma or ocular hypertension. Clin Ophthalmol (Auckland, NZ). 2020;14:221\u201330.","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"key":"1022_CR24","first-page":"1289","volume":"37","author":"M Aihara","year":"2020","unstructured":"Aihara M, Sekiya T. Phase 3 study to evaluate the efficacy and safety of novel brimonidine\/brinzolamide ophthalmic suspension compared with brimonidine ophthalmic solution in patients with primary open-angle glaucoma (broad-definition) or ocular hypertension. J Eye. 2020;37:1289\u201398 (in Japanese).","journal-title":"J Eye"},{"key":"1022_CR25","first-page":"1299","volume":"37","author":"M Aihara","year":"2020","unstructured":"Aihara M, Sekiya T. Phase 3 study to evaluate the efficacy and safety of novel brimonidine\/brinzolamide ophthalmic suspension compared with brinzolamide ophthalmic solution in patients with primary open-angle glaucoma (broad-definition) or ocular hypertension. J Eye. 2020;37:1299\u2013308 (in Japanese).","journal-title":"J Eye"},{"key":"1022_CR26","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s10384-022-00930-3","volume":"66","author":"K Inoue","year":"2022","unstructured":"Inoue K, Kunimatsu-Sanuki S, Ishida K, Tomita G. Intraocular pressure-lowering effects and safety of brimonidine\/brinzolamide fixed combination after switching from other medications. Jpn J Ophthalmol. 2022;66:440\u20136.","journal-title":"Jpn J Ophthalmol"},{"key":"1022_CR27","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2105\/AJPH.94.3.361","volume":"94","author":"DC Des Jarlais","year":"2004","unstructured":"Des Jarlais DC, Lyles C, Crepaz N. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am J Public Health. 2004;94:361\u20136.","journal-title":"Am J Public Health"},{"key":"1022_CR28","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/00061198-200404000-00008","volume":"13","author":"A Neelakantan","year":"2004","unstructured":"Neelakantan A, Vaishnav HD, Iyer SA, Sherwood MB. Is addition of a third or fourth antiglaucoma medication effective? J Glaucoma. 2004;13:130\u20136.","journal-title":"J Glaucoma"},{"key":"1022_CR29","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1080\/14740338.2017.1346083","volume":"16","author":"JA Lusthaus","year":"2017","unstructured":"Lusthaus JA, Goldberg I. Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation. Expert Opin Drug Saf. 2017;16:1071\u20138.","journal-title":"Expert Opin Drug Saf"},{"key":"1022_CR30","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1016\/j.ophtha.2014.06.022","volume":"121","author":"T Aung","year":"2014","unstructured":"Aung T, Laganovska G, Hernandez Paredes TJ, Branch JD, Tsorbatzoglou A, Goldberg I. Twice-daily brinzolamide\/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension. Ophthalmology. 2014;121:2348\u201355.","journal-title":"Ophthalmology"},{"key":"1022_CR31","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s12325-014-0168-y","volume":"31","author":"SA Gandolfi","year":"2014","unstructured":"Gandolfi SA, Lim J, Sanseau AC, Parra Restrepo JC, Hamacher T. Randomized trial of brinzolamide\/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension. Adv Ther. 2014;31:1213\u201327.","journal-title":"Adv Ther"},{"key":"1022_CR32","first-page":"679","volume":"29","author":"M Araie","year":"2012","unstructured":"Araie M, Yamazaki Y, Sugiyama K, Kuwayama Y, Tanihara H. Long-term safety and efficacy of brimonidine ophthalmic solution in patients with primary open angle glaucoma or ocular hypertension. J Eye. 2012;29:679\u201386 (in Japanase).","journal-title":"J Eye"},{"key":"1022_CR33","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/archopht.125.5.717-a","volume":"125","author":"JA Alvarado","year":"2007","unstructured":"Alvarado JA. Reduced ocular allergy with fixed-combination 0.2% brimonidine-0.5% timolol. Arch Ophthalmol. 2007;125:717 (author reply -8).","journal-title":"Arch Ophthalmol"}],"updated-by":[{"DOI":"10.1007\/s10384-023-01025-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000}}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-023-01022-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-023-01022-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-023-01022-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T08:10:21Z","timestamp":1700640621000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-023-01022-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,19]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1022"],"URL":"https:\/\/doi.org\/10.1007\/s10384-023-01022-6","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10384-023-01025-3","asserted-by":"object"}]},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,19]]},"assertion":[{"value":"19 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10384-023-01025-3","URL":"https:\/\/doi.org\/10.1007\/s10384-023-01025-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R. Sakata, Grant (Santen, Novartis, TOMEY); S. Mizoue, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Santen, Kowa, Novartis, Otsuka Pfizer); K. Yoshikawa, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Santen, Otsuka, Novartis, RE Medical), M. Adachi, None; S. Ohkubo, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Santen, Pfizer, Viatris, Alcon, JFC Sales Plan, Beeline, Nitto Medic, Sucampo, ZEISS, JFC, Heidelberg Engineering, Otsuka); N. Hamada, None; T. Naito, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Santen, Otsuka, Novartis, Kowa); T. Muramatsu, None; T. Hara, None; R. Asato, None; M. Aihara, Consulting fees (Santen, Senju, Alcon, Pfizer, Kowa, Otsuka, Wakamoto, Glaukos, HOYA, IRIDEX, Astellas), Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Santen, Senju, Alcon, Pfizer, Kowa, Otsuka, Wakamoto, Glaukos, HOYA, IRIDEX, Astellas, CANON, ZEISS).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}